Lysine-specific demethylase 1 as a therapeutic cancer target: observations from preclinical study.

IF 4.6 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert Opinion on Therapeutic Targets Pub Date : 2023-07-01 Epub Date: 2023-12-30 DOI:10.1080/14728222.2023.2288277

Jessica D Johnson, Salvador Alejo, Sridharan Jayamohan, Gangadhara R Sareddy

{"title":"Lysine-specific demethylase 1 as a therapeutic cancer target: observations from preclinical study.","authors":"Jessica D Johnson, Salvador Alejo, Sridharan Jayamohan, Gangadhara R Sareddy","doi":"10.1080/14728222.2023.2288277","DOIUrl":null,"url":null,"abstract":"Introduction: Lysine-specific histone demethylase 1A (KDM1A/LSD1) has emerged as an important therapeutic target in various cancer types. LSD1 regulates a wide range of biological processes that influence cancer development, progression, metastasis, and therapy resistance. However, recent studies have revealed novel aspects of LSD1 biology, shedding light on its involvement in immunogenicity, antitumor immunity, and DNA damage response. These emerging findings have the potential to be leveraged in the design of effective LSD1-targeted therapies.Areas covered: This paper discusses the latest developments in the field of LSD1 biology, focusing on its role in regulating immunogenicity, antitumor immunity, and DNA damage response mechanisms. The newfound understanding of these mechanisms has opened possibilities for the development of novel LSD1-targeted therapies for cancer treatment. Additionally, the paper provides an overview of LSD1 inhibitor-based combination therapies for the treatment of cancer.Expert opinion: Exploiting LSD1 role in antitumor immunity and DNA damage response provides cues to not only understand the LSD1-resistant mechanisms but also rationally design new combination therapies that are more efficient and less toxic than monotherapy. The exploration of LSD1 biology and the development of LSD1-targeted therapies hold great promise for the future of cancer treatment.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10872912/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14728222.2023.2288277","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/30 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Lysine-specific histone demethylase 1A (KDM1A/LSD1) has emerged as an important therapeutic target in various cancer types. LSD1 regulates a wide range of biological processes that influence cancer development, progression, metastasis, and therapy resistance. However, recent studies have revealed novel aspects of LSD1 biology, shedding light on its involvement in immunogenicity, antitumor immunity, and DNA damage response. These emerging findings have the potential to be leveraged in the design of effective LSD1-targeted therapies.

Areas covered: This paper discusses the latest developments in the field of LSD1 biology, focusing on its role in regulating immunogenicity, antitumor immunity, and DNA damage response mechanisms. The newfound understanding of these mechanisms has opened possibilities for the development of novel LSD1-targeted therapies for cancer treatment. Additionally, the paper provides an overview of LSD1 inhibitor-based combination therapies for the treatment of cancer.

Expert opinion: Exploiting LSD1 role in antitumor immunity and DNA damage response provides cues to not only understand the LSD1-resistant mechanisms but also rationally design new combination therapies that are more efficient and less toxic than monotherapy. The exploration of LSD1 biology and the development of LSD1-targeted therapies hold great promise for the future of cancer treatment.

查看原文本刊更多论文

赖氨酸特异性去甲基酶1作为治疗癌症的靶点:来自临床前研究的观察

赖氨酸特异性组蛋白去甲基化酶1A (KDM1A/LSD1)已成为多种癌症类型的重要治疗靶点。LSD1调节影响癌症发生、进展、转移和治疗耐药的广泛生物学过程。然而，最近的研究揭示了LSD1生物学的新方面，揭示了它在免疫原性、抗肿瘤免疫和DNA损伤反应中的作用。这些新发现有可能用于设计有效的lsd1靶向治疗方法。涵盖领域:本文讨论了LSD1在调节免疫原性、抗肿瘤免疫和DNA损伤反应机制方面的最新进展。对这些机制的新认识为开发用于癌症治疗的新型lsd1靶向疗法开辟了可能性。此外，本文还概述了以LSD1抑制剂为基础的联合治疗癌症的方法。专家意见:利用LSD1在抗肿瘤免疫和DNA损伤应答中的作用，不仅为了解LSD1耐药机制提供了线索，而且为合理设计新的联合治疗提供了线索，这些联合治疗比单一治疗更有效，毒性更小。LSD1生物学的探索和LSD1靶向治疗的发展为未来的癌症治疗带来了巨大的希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Therapeutic Targets 医学-药学

CiteScore

8.90

自引率

1.70%

发文量

审稿时长

3 months

期刊介绍： The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials. The Editors welcome: Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development. Articles should not include clinical information including specific drugs and clinical trials. Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs. The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.

文献相关原料

公司名称	产品信息	采购帮参考价格